Abstract
Background: The coronavirus disease (COVID-19) outbreak has become a global pandemic. COVID-19 patients with olfactory loss and taste disorders have received considerable attention.
Introduction
Early in the SARS-CoV-2 pandemic, clinicians noticed a surge in patients reporting a sudden loss of smell (anosmia) and taste (ageusia). However, it wasn't immediately clear how prevalent these symptoms were, whether they were caused by physical blockages (like a "stuffy nose" in a common cold), or how quickly patients recovered.
This study sought to quantify the incidence of these dysfunctions in a clinical setting, investigate the physical state of the nasal cavity using endoscopy and CT scans, and track the prognosis of sensory recovery over a three-week period. Olfactory and gustatory dysfunctions are not just side effects; they are frequently the initial or even sole symptoms of infection.
Methods
The researchers conducted a prospective study of 71 confirmed COVID-19 patients admitted to Beijing DiTan Hospital in March 2020. Patients with pre-existing long-term anosmia, acute nasal disease, diabetes, or those in intensive care were excluded to ensure results were specifically linked to the viral infection.
Their approach combined subjective reporting with objective clinical imaging:
- Clinical Screening: All patients underwent endoscopic nasal examinations. A subset (7 cases) received CT scans of the nasal cavity to check for physical obstructions or inflammation.
- Sensory Assessment: Patients used a Visual Analogue Scale (VAS)—ranging from 0 (total loss) to 10 (normal)—to rate their sense of smell and taste on the 1st, 7th, and 21st days of hospitalization.
- Neurological Investigation: In one case involving a headache, Cerebrospinal Fluid (CSF) was tested via RT-qPCR to check for direct viral invasion of the central nervous system.
Key Insights and Results
The "Invisible" Symptom
Unlike the common cold or flu, where smell is lost due to mucus and swelling, these patients showed no purulent mucus or physical obstruction in the olfactory cleft on CT scans. This suggests the virus attacks the sensory system at a cellular or molecular level rather than through mechanical blockage. The authors highlight that while the virus affects smell, it likely targets non-neuronal support cells (sustentacular cells) that express the ACE2 receptor, rather than the olfactory neurons themselves.
Prevalence and Recovery
The study found that 39.4% of patients reported olfactory dysfunction, and 35.2% reported gustatory dysfunction. There is a high correlation between the two; 89.3% of patients with smell loss also experienced taste loss. For 15.49% of patients, anosmia was the initial symptom, and for five patients, it was their only complaint.
The prognosis is generally positive. As shown in the data below, median VAS scores improved significantly over three weeks as support cells likely regenerated.
By the three-week mark, 39.29% of patients with olfactory issues and 48% with gustatory issues had achieved complete recovery. The median olfactory VAS score improved from 0 at the initial stage to 7.5 after three weeks.
Limitations and Future Work
The authors acknowledge several constraints, including a small sample size (71 patients) from a single center and the subjectivity of self-reported VAS scores. By excluding ICU patients, the study may not reflect sensory dysfunction patterns in severe cases. While CSF testing in one patient was negative for the virus, more extensive research is needed to definitively rule out the neurotropic potential of SARS-CoV-2 in the broader population.
Conclusion
Sensory loss serves as a critical early warning sign for COVID-19, often appearing before or in the absence of other symptoms. Because these losses occur without physical nasal obstruction, they represent a unique clinical marker that should prompt immediate self-isolation and testing.
Summary updated